Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan 31:9:1-11.
doi: 10.2147/ORR.S105227. eCollection 2017.

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice

Jan Beyer-Westendorf  1 , Patrick Mouret  2 , Alexander Gg Turpie  3
Affiliations
Review

Rivaroxaban for venous thromboembolism prevention after major orthopedic surgery: translating trial data into routine clinical practice

Jan Beyer-Westendorf et al. Orthop Res Rev. .

Abstract

An established standard of care for the prevention of venous thromboembolism after major orthopedic surgery has been subcutaneous low-molecular-weight heparin. The non-vitamin K antagonist oral anticoagulant rivaroxaban has demonstrated superior efficacy and similar safety to all tested regimens of enoxaparin in large Phase III clinical studies of venous thromboembolism prevention after elective hip and knee arthroplasty. Despite regulatory approval of rivaroxaban for this indication, concerns remain among physicians regarding its optimal and effective use in routine clinical practice. Real-life studies, such as XAMOS and ORTHO-TEP, are providing physicians with more information on the routine use of rivaroxaban for venous thromboembolism prevention after orthopedic surgery, helping to establish its safety and effectiveness in everyday clinical care. Among the most important issues are the risk of bleeding complications, wound healing, timing of first dose, impact of type of anesthesia on thromboprophylaxis effectiveness, patient comorbidities and comedication use, periprocedural management, associated costs, and clinical outcomes in trauma-related fractures. Many of these issues are difficult to study in randomized, double-blind, Phase III trials, and can be assessed more readily using real-life data. In particular, real-life or noninterventional studies lack many of the strict inclusion and exclusion criteria associated with Phase III trials and involve unselected patients who often present with significant comorbidities or comedication use.

Keywords: anticoagulants; arthroplasty; orthopedics; rivaroxaban; thrombosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure JBW has received honoraria and research support from Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, and Pfizer. PM has been a consultant for and has received honoraria from Bayer HealthCare, Sanofi, and Bristol-Myers Squibb. AGGT has been a consultant for Bayer HealthCare, Janssen Pharmaceutical Research and Development LLC, Astellas, Portola, and Takeda. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Kaplan–Meier analysis of length of hospital stay with rivaroxaban and fondaparinux. Notes: Subgroups of patients without complications (A), with and without VTE (B), with and without major bleeding (C), and with and without surgical revisions (D). Owing to the interference of complications and confounding factors over time, these analyses are of a descriptive nature only, and were not assessed for statistical significance. Adapted with permission from the Journal of Thrombosis and Haemostasis (John Wiley & Sons Ltd, Chichester, UK). Beyer-Westendorf J, Lützner J, Donath L, et al. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry. 2012;10(10):2045–2052. © 2012 International Society on Thrombosis and Haemostasis. Abbreviations: CI, confidence interval; VTE, venous thromboembolism.
Figure 2
Figure 2
Kaplan–Meier analysis of length of hospital stay with rivaroxaban and LMWH. Notes: Subgroups of patients without complications (A), with and without VTE (B), with and without major bleeding (C), and with and without surgical revisions (D). Owing to the interference of complications and confounding factors over time, these analyses are of a descriptive nature only, and were not assessed for statistical significance. Adapted with permission from the Journal of Thrombosis and Haemostasis (Schattauer Publishers, Stuttgart, Germany). Beyer-Westendorf J, Lützner J, Donath L, et al. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry. 2013;109(1):154–163. © Schattauer Publishers, Stuttgart. Abbreviations: LMWH, low-molecular-weight heparin; VTE, venous thromboembolism.
See this image and copyright information in PMC

References

    1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest. 2008;133(6 Suppl):381S–453S. - PubMed
    1. Hamidi V, Ringerike T, Hagen G, Reikvam A, Klemp M. New anticoagulants as thromboprophylaxis after total hip or knee replacement. Int J Technol Assess Health Care. 2013;29(3):234–243. - PubMed
    1. Friedman RJ. New oral anticoagulants for thromboprophylaxis after total hip or knee arthroplasty. Orthopedics. 2009;32(12 Suppl):79–84. - PubMed
    1. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765–2775. - PubMed
    1. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31–39. - PubMed

LinkOut - more resources